Gene therapy injection for advanced retinitis pigmentosa
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests an investigational gene therapy injection (UGX202) for people with advanced retinitis pigmentosa. The goal is to see if the injection is safe and can help preserve or improve vision in people who still have some memory of seeing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have retinitis pigmentosa (RP) that is not part of a syndrome (does not affect other body parts).
- In the study eye, your vision is better than 'hand motion' (roughly 20/2000).
- You still have some memory of seeing well.
- Your eyeglass prescription is between -9 and +6 diopters (moderate nearsightedness to moderate farsightedness).
- You haven't had gene therapy in either eye and haven't taken part in another investigational drug study in the past 90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gene therapy called UGX202 for people with advanced retinitis pigmentosa, an eye disease that causes vision loss. The goal is to see if it is safe and if it can help improve vision.
This study tests a new gene therapy that may help people with advanced retinitis pigmentosa see better. It uses a modified virus to deliver a light-sensitive protein to the retina, and the trial compares the real treatment to a sham (fake) procedure to check safety and effectiveness.
This study tests a new gene therapy for people with advanced rod-cone dystrophy, a genetic condition that causes progressive vision loss. The treatment is given as an injection into the eye, and the study aims to see if it is safe and if it can help improve or preserve vision.
This trial tests a new peptide therapy for people with retinitis pigmentosa (RP), a genetic eye disease that causes vision loss. The goal is to see if the treatment is safe and can help slow or improve vision loss.
This early study tests a gene therapy designed for people whose vision problems are caused by an RPGR genetic change. It may help slow or improve the eye disease by treating the underlying cause.
This trial tests two doses of a gene therapy (AGTC-501) in males who already had one eye treated with a similar gene therapy for X-linked retinitis pigmentosa caused by RPGR mutations. The goal is to see if the treatment is safe and can help preserve or improve vision.
Hear when a new Retinitis Pigmentosa (RP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.